BioStock: CombiGene focuses on further in-licensing

The FDA has recently approved bluebird bio’s new potentially curative gene therapy treatment for the blood disease beta-thalassemia, a treatment could cost close to 3 million USD per dose. For Swedish gene therapy company CombiGene, whose candidate CG01 is being developed in collaboration with Spark Therapeutics, bluebird’s approval is a barometer of the interest in the gene therapy field in general.

Read the article at biostock.se:

https://www.biostock.se/en/2022/08/combigene-focuses-on-further-in-licensing/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/